Olivier Loeillot
Net worth: 8 M $ as of 2026-10-30
Net worth: 8 M $ as of 2026-10-30
Olivier Dominique Loeillot is President, Chief Executive Officer & Director at Repligen Corp.
since 2024.
Formerly, Mr. Loeillot was Chief Executive Officer at Ascensus Specialties LLC from 2022 to 2023, Director at Cytiva Bioscience Holding Ltd. from 2020 to 2022, Senior Vice President Bioprocess Division at Cytiva CTH Holding Ltd. from 2017 to 2020, VP Sales LONZA at Lonza AG from 2008 to 2010, Sales Director at Rhodia Pharma Solutions Ltd. from 2002 to 2003, and held roles as Director at Puridify Ltd., Management Partner at New Mountain Capital LLC, and other positions.
Mr. Loeillot earned an MBA from Emlyon Business School in 1994.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REPLIGEN CORPORATION 0.07% | 2026-10-04 | 45,788 ( 0.07% ) | 8 M $ | 2026-10-30 |
| Companies | Position | Start |
|---|---|---|
| REPLIGEN CORPORATION | Chief Executive Officer | 2024-08-31 |
| Companies | Position | End |
|---|---|---|
Ascensus Specialties LLC
Ascensus Specialties LLC Chemicals: Major DiversifiedProcess Industries Operates as a chemical company | Chief Executive Officer | 2023-05-31 |
Cytiva Bioscience Holding Ltd.
Cytiva Bioscience Holding Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Director/Board Member | 2022-08-31 |
GE Healthcare CTH Holding Ltd.
GE Healthcare CTH Holding Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | 2020-03-31 |
Lonza AG
Lonza AG BiotechnologyHealth Technology Engages in developing, producing and selling pharmaceutical and chemical products | Sales & Marketing | 2010-08-31 |
Rhodia Pharma Solutions Ltd.
Rhodia Pharma Solutions Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Private Equity Investor | 2003-05-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Repligen Corp.
Repligen Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures biologic drugs | Health Technology |
New Mountain Capital LLC
New Mountain Capital LLC Investment ManagersFinance New Mountain Capital invests in middle market companies located in the United States with an enterprise value of USD 100 - 1000 million. The firm focuses on a broad range of sectors and industries. It provides financing for add-on acquisitions, buyout and growth transactions with a transaction size ranging USD 100 - 500 million. It also acquires majority control and minority equity positions. | Finance |
Rhodia Pharma Solutions Ltd.
Rhodia Pharma Solutions Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Lonza AG
Lonza AG BiotechnologyHealth Technology Engages in developing, producing and selling pharmaceutical and chemical products | Health Technology |
Puridify Ltd.
Puridify Ltd. Miscellaneous Commercial ServicesCommercial Services Develops bioprocessing technologies | Commercial Services |
Emlyon Business School
Emlyon Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascensus Specialties LLC
Ascensus Specialties LLC Chemicals: Major DiversifiedProcess Industries Operates as a chemical company | Process Industries |
GE Healthcare CTH Holding Ltd.
GE Healthcare CTH Holding Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Cytiva Bioscience Holding Ltd.
Cytiva Bioscience Holding Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Select your edition
All financial news and data tailored to specific country editions